Where does NeoDiagnostix, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), NeoDiagnostix, Inc. ranks #49,014 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does NeoDiagnostix, Inc. hold?

NeoDiagnostix, Inc. holds 5 US utility patents granted between 2015 and 2021, spanning 5 technology areas.

What is NeoDiagnostix, Inc.'s Innovation Score?

NeoDiagnostix, Inc. has an Innovation Score of 29.1 out of 100 (30th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is NeoDiagnostix, Inc.'s patent grant rate increasing or decreasing?

NeoDiagnostix, Inc.'s recent grant velocity is -33% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for NeoDiagnostix, Inc.'s patents?

NeoDiagnostix, Inc.'s patents average 26.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the NeoDiagnostix, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

NeoDiagnostix, Inc.

Q: What technology areas does NeoDiagnostix, Inc. focus on?

NeoDiagnostix, Inc.'s top technology area is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes) with 5 patents, ranking #840 of 2,502 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Neodiagnostix ranks #49,014 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 5 technology areas.

#49,014
of 49,997 US assignees by volume: 30th percentile
by Innovation Score (29.1/100): 26.4
avg claims per patent: -33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R49014 · US Corporation #49,014 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 5 grants
BOTTOM-DECILE #49,014/49,997
PHOTO-FINISH Near-Miss Management
CPC-NARROW C12Q · 5 areas
INNOV-THIN 29.1/100
CLAIMS-DENSE 26.4 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -33% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Near-Miss Management LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Neodiagnostix’s 29.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (21%) Velocity 0.0 pts (0%) Breadth 7.9 pts (27%) Claim depth 15.0 pts (52%)

Qualcomm Incorporated · highest

85
NeoDiagnostix · this assignee

29
3D Lighting… · lowest

7

What this shows Neodiagnostix's Innovation Score is 29.1/100 (30th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Neodiagnostix?

Each dot is one of Neodiagnostix’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neodiagnostix’s own 26.4 claims/patent is ABOVE the 12.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Neodiagnostix vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Neodiagnostix's grants concentrate

NeoDiagnostix, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2015 (2 grants) versus a trough of 1 in 2017. By volume, Neodiagnostix sits between Near-Miss Management LLC and Neosinus Health Inc..

Near-miss Managem…

5
Necksgen

5
Nectero Medical

5
Neo Mechanics

5
Neogenis Labs

5
Neomend

5
Neores AB

5
Neosinus Health

5
Neodiagnostix ◀

5

What this shows NeoDiagnostix holds 5 patents at rank #49,133, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near NeoDiagnostix

By rank, the assignees closest to #49,133 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in NeoDiagnostix's primary technology class.

Neodiagnostix's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 30th percentile higher than 30% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

NeoDiagnostix, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	40.0%
2017	1	20.0%
2021	2	40.0%

Which technologies does NeoDiagnostix, Inc. patent most?

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 5

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

G06V - Image OR Video Recognition OR Understanding 2

G06T - Image Data Processing OR Generation, IN General 2

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

NeoDiagnostix, Inc.'s patent record in context - here's where to go next.

NeoDiagnostix, Inc.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 100% of its portfolio - see every assignee active in that class. Explore C12Q
Ranked #49,014 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare NeoDiagnostix, Inc. against Near-Miss Management LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.